• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Reply to “GLP1RA versus SGLT2i tended to have more favorable ischemic outcomes including stroke?”
We appreciated Du et al.'s valuable comments on our recent study. [1] As described by the author, the reduced trend of a composite ischemic outcome in the glucagon-like peptide-1 receptor agonists (GLP1RA) group, compared to the sodium-glucose cotransporter 2 inhibitors (SGLT2i) group, was mainly derived by acute coronary syndrome (ACS). However, despite the lack of statistical significance due to the low event rates, it was noted that the annualized rates (per 100 person-year) for each component of ischemic events were lower in the GLP1RA group than SGLT2i group: ACS 0.25 vs.
Source: International Journal of Cardiology - August 23, 2022 Category: Cardiology Authors: In-Chang Hwang, Chee Hae Kim Tags: Letter to the Editor Source Type: research

GLP1RA versus SGLT2i tended to have more favorable ischemic outcomes including stroke?
In Kim and colleagues' article [1] reporting a retrospective cohort study aiming to assess the cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1RA) in patients with type 2 diabetes mellitus (T2DM), one main conclusion is that GLP1RA tended to have more favorable ischemic outcomes. To some extent, this conclusion is exaggerated because GLP1RA and SGLT2i had the similar risks of coronary revascularization and stroke according to the main results of this article.
Source: International Journal of Cardiology - July 12, 2022 Category: Cardiology Authors: Lixin Du, Yu Zhang, Pan Wang, Zhigang Li, Yunhui Zhao, Jianpeng Yuan Tags: Letter to the Editor Source Type: research

Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus
Background:The differential benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) in cardiovascular or renal outcomes have not been fully investigated.Methods: Patients with diabetes prescribed SGLT2i or GLP1RA were retrospectively identified. Patients treated with antihyperglycemic medications other than SGLT2i or GLP1RA were used as a control group. Primary outcomes were composite ischemic events (acute coronary syndrome, coronary revascularization, and stroke) and a composite of heart failure and renal events (hospitalization for heart failure, renal death,...
Source: International Journal of Cardiology - June 14, 2022 Category: Cardiology Authors: Chee Hae Kim, In-Chang Hwang, Hong-Mi Choi, Chang Ho Ahn, Yeonyee E. Yoon, Goo-Yeong Cho Source Type: research